Anthem Biosciences Ltd files SEBI 29(2) disclosure for share acquisition by Aruna Ganesh

What Anthem Biosciences announced

On 19 June 2026, Anthem Biosciences Ltd (BSE: 544449) submitted a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing informs the market that Aruna Ganesh has acquired a substantial block of the company’s shares, thereby triggering the mandatory reporting requirement.

Regulation 29(2) – when a filing is required

Regulation 29(2) mandates that any person who acquires, directly or indirectly, more than 1 % of the voting share capital of a listed entity must disclose the acquisition to the stock exchange within two working days. The purpose is to ensure transparency and give existing shareholders timely information about changes in control or significant shareholdings.

Details of the acquisition

The BSE notice does not provide the exact number of shares, the percentage held, or the consideration paid by Aruna Ganesh. The filing merely confirms that the acquisition crossed the 1 % threshold and therefore required a Regulation 29(2) disclosure. No further information on the intent behind the purchase, any future share‑sale plans, or board approvals is included in the document.

Key facts at a glance

Why this matters for investors

A Regulation 29(2) filing signals that a new significant shareholder has entered the company’s capital structure. While the filing does not reveal the size of the stake, the mere fact that the threshold has been crossed may lead to increased scrutiny of the shareholder’s motives and potential influence on corporate governance. Investors should monitor subsequent disclosures, such as any filing under Regulation 29(3) if the shareholding changes further, or any board communications that might arise from the new stakeholder.

Conclusion

Anthem Biosciences has complied with SEBI’s disclosure requirements by reporting Aruna Ganesh’s substantial share acquisition on 19 June 2026. The filing provides limited quantitative detail, and further information may be disclosed in future regulatory filings or company announcements.